Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab brengitecan - Sichuan Baili Pharmaceutical

Next Previous
Drug Profile

Trastuzumab brengitecan - Sichuan Baili Pharmaceutical

Alternative Names: BL-M07D1; T-Bren - Sichuan Baili Pharmaceutical

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Developer Fudan University; Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Gastric cancer

Highest Development Phases

  • Phase III Adenocarcinoma; Biliary cancer; HER2 positive breast cancer; Non-small cell lung cancer
  • Phase I/II Gynaecological cancer; Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 23 Jul 2026 Sichuan Baili Pharmaceutical plans a phase III trial for Colorectal cancer(Metastatic disease, Late-stage disease, Second-line therapy or greater) in China(IV, Infusion) in August 2026 (NCT07730489)
  • 07 Jul 2026 Phase-III clinical trials in Biliary cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07606599)
  • 01 Jul 2026 Sichuan Baili Pharmaceutical plans a phase II trial for Breast cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV, Infusion), in July 2027 (NCT07678957)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top